Login to Your Account



Merck to Move Forward with Oncothyreon Cancer Vaccine

By Catherine Shaffer
Staff Writer

Thursday, September 26, 2013
An anxious wait for Oncothyreon Inc. has come to an end, as Merck KGaA announced it would continue development of tecemotide (formerly Stimuvax) following last year’s Phase III trial miss.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription